EP 3525798 A4 20200708 - METHODS FOR REDUCING PROTEINURIA IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY
Title (en)
METHODS FOR REDUCING PROTEINURIA IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY
Title (de)
VERFAHREN ZUR VERRINGERUNG DER PROTEINURIE BEI EINEM MENSCHLICHEN PROBANDEN, DER AN IMMUNGLOBULIN-A-NEPHROPATHIE LEIDET
Title (fr)
MÉTHODES DE RÉDUCTION DE LA PROTÉINURIE CHEZ UN SUJET HUMAIN SOUFFRANT D'UNE NÉPHROPATHIE AUX IMMUNOGLOBULINES A
Publication
Application
Priority
- US 201662407979 P 20161013
- US 201715399524 A 20170105
- US 201715470647 A 20170327
- US 201762527926 P 20170630
- US 2017056386 W 20171012
Abstract (en)
[origin: WO2018071701A1] In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation.
IPC 8 full level
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 13/12 (2006.01); C07K 16/40 (2006.01)
CPC (source: EP KR)
A01K 67/0276 (2013.01 - EP KR); A61K 48/00 (2013.01 - EP); A61P 7/00 (2018.01 - EP KR); A61P 13/12 (2018.01 - EP KR); C07K 16/40 (2013.01 - EP KR); C12N 9/6424 (2013.01 - EP); C12Y 304/21104 (2013.01 - EP); A01K 2217/075 (2013.01 - EP); A01K 2227/105 (2013.01 - EP); A01K 2267/035 (2013.01 - EP); A61K 2039/505 (2013.01 - EP KR); C07K 2317/24 (2013.01 - EP KR); C07K 2317/54 (2013.01 - EP KR); C07K 2317/622 (2013.01 - EP KR); C07K 2317/76 (2013.01 - EP KR); C07K 2317/92 (2013.01 - EP KR); C07K 2317/94 (2013.01 - EP KR); C07K 2319/00 (2013.01 - EP KR)
Citation (search report)
- [X] WO 2015058143 A1 20150423 - OMEROS CORP [US], et al
- [Y] WO 2012151481 A1 20121108 - OMEROS CORP [US], et al
- [XY] US 2013266560 A1 20131010 - DEMOPULOS GREGORY A [US], et al
- [E] US 2018153988 A1 20180607 - DEMOPULOS GREGORY A [US], et al
- See also references of WO 2018071701A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018071701 A1 20180419; AU 2017342428 A1 20190523; AU 2017342428 B2 20210204; BR 112019007426 A2 20190702; CA 3039927 A1 20180419; CA 3039927 C 20231010; CA 3210384 A1 20180419; CL 2019000909 A1 20190614; CL 2019003485 A1 20200413; CN 110177557 A 20190827; CN 116726163 A 20230912; EP 3525798 A1 20190821; EP 3525798 A4 20200708; GE P20247587 B 20240125; IL 265981 A 20190630; JO P20190068 A1 20190401; JP 2019534271 A 20191128; JP 6893554 B2 20210623; KR 102348939 B1 20220112; KR 20190063475 A 20190607; MA 46541 A 20190821; MX 2019004074 A 20190610; NZ 753260 A 20211126; PH 12019500711 A1 20191118; SG 11201902941U A 20190530; UA 126908 C2 20230222; ZA 201902933 B 20230531
DOCDB simple family (application)
US 2017056386 W 20171012; AU 2017342428 A 20171012; BR 112019007426 A 20171012; CA 3039927 A 20171012; CA 3210384 A 20171012; CL 2019000909 A 20190404; CL 2019003485 A 20191128; CN 201780060710 A 20171012; CN 202310450575 A 20171012; EP 17861108 A 20171012; GE AP2017015070 A 20171012; IL 26598119 A 20190411; JO P20190068 A 20170616; JP 2019520140 A 20171012; KR 20197012865 A 20171012; MA 46541 A 20171012; MX 2019004074 A 20171012; NZ 75326017 A 20171012; PH 12019500711 A 20190401; SG 11201902941U A 20171012; UA A201904866 A 20171012; ZA 201902933 A 20190510